Adverse reactions associated with meningococcal group B vaccine (4CMenB) in adults in special situations
Fuente:
Redalyc
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artículo científico |
| Sprache: | en |
| Veröffentlicht: |
Sociedad Española de Farmacia Hospitalaria
2018
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1876481131805671424 |
|---|---|
| author | María Fernández-Prada |
| author_facet | María Fernández-Prada |
| contents | Adverse reactions associated with meningococcal group B vaccine (4CMenB) in adults in special situations María Fernández-Prada Carmen Martínez-Ortega Lara Hidalgo-Peña Clara Álvarez-Vázquez Rodrigo Aguirre-del Pino Ismael Huerta-González Medicina 4CMenB Vaccines Meningitis Meningococcus Adverse effects Objective: To know the safety profile of the 4CMenB vaccine in adults in special situations.Method: Security prospective study of phase IV. Inclusion criteria and some vaccination conditions were applied. The adverse reactions described in the data sheet were collected. The adverse reactions evaluation was performed 24 hours after vaccination (“requested”) and during the first seven days (“not requested”).Results: 72 patients were included (54.2% men, mean age 52.5 years, 81.9% anatomic asplenia). The frequency of fever > 38 ºC in the first 24 hours of vaccination was higher than the observed in the summary of product characteristics for the group of adults (12.5% vs. not known). More than 75% of the patients reported local pain in the first hours (average of the Analog Visual Scale score 3.22 (95% CI: 2.67-3.76) in the first dose and 3.23 (95% CI: 2.69-3.78) in the second dose). There were no statistically significant differences. 97.22% registered symptoms until 7 days after vaccination.Conclusions: 4CMenB shows a good safety profile in adults in special situations. The frequency of fever > 38 ºC is higher than expected. Local pain is the most frequently recorded adverse reactions, but the intensity is low. These results suggest a review of the situation in order to suggest a possible modification of the summary of product characteristics of the vaccine. 2018 artículo científico 1130-6343 https://www.redalyc.org/articulo.oa?id=365962347003 https://www.redalyc.org/journal/3659/365962347003/ https://www.redalyc.org/journal/3659/365962347003/html/ https://www.redalyc.org/journal/3659/365962347003/365962347003.epub https://www.redalyc.org/journal/3659/365962347003/movil 10.7399/fh.10989 en http://www.redalyc.org/revista.oa?id=3659 Farmacia Hospitalaria application/pdf Sociedad Española de Farmacia Hospitalaria Farmacia Hospitalaria (España) Num.5 Vol.42 |
| format | Artículo científico |
| id | redalyc_365962347003 |
| institution | Redalyc |
| language | en |
| publishDate | 2018 |
| publisher | Sociedad Española de Farmacia Hospitalaria |
| spellingShingle | Adverse reactions associated with meningococcal group B vaccine (4CMenB) in adults in special situations María Fernández-Prada Medicina 4CMenB Vaccines Meningitis Meningococcus Adverse effects Adverse reactions associated with meningococcal group B vaccine (4CMenB) in adults in special situations María Fernández-Prada Carmen Martínez-Ortega Lara Hidalgo-Peña Clara Álvarez-Vázquez Rodrigo Aguirre-del Pino Ismael Huerta-González Medicina 4CMenB Vaccines Meningitis Meningococcus Adverse effects Objective: To know the safety profile of the 4CMenB vaccine in adults in special situations.Method: Security prospective study of phase IV. Inclusion criteria and some vaccination conditions were applied. The adverse reactions described in the data sheet were collected. The adverse reactions evaluation was performed 24 hours after vaccination (“requested”) and during the first seven days (“not requested”).Results: 72 patients were included (54.2% men, mean age 52.5 years, 81.9% anatomic asplenia). The frequency of fever > 38 ºC in the first 24 hours of vaccination was higher than the observed in the summary of product characteristics for the group of adults (12.5% vs. not known). More than 75% of the patients reported local pain in the first hours (average of the Analog Visual Scale score 3.22 (95% CI: 2.67-3.76) in the first dose and 3.23 (95% CI: 2.69-3.78) in the second dose). There were no statistically significant differences. 97.22% registered symptoms until 7 days after vaccination.Conclusions: 4CMenB shows a good safety profile in adults in special situations. The frequency of fever > 38 ºC is higher than expected. Local pain is the most frequently recorded adverse reactions, but the intensity is low. These results suggest a review of the situation in order to suggest a possible modification of the summary of product characteristics of the vaccine. 2018 artículo científico 1130-6343 https://www.redalyc.org/articulo.oa?id=365962347003 https://www.redalyc.org/journal/3659/365962347003/ https://www.redalyc.org/journal/3659/365962347003/html/ https://www.redalyc.org/journal/3659/365962347003/365962347003.epub https://www.redalyc.org/journal/3659/365962347003/movil 10.7399/fh.10989 en http://www.redalyc.org/revista.oa?id=3659 Farmacia Hospitalaria application/pdf Sociedad Española de Farmacia Hospitalaria Farmacia Hospitalaria (España) Num.5 Vol.42 |
| title | Adverse reactions associated with meningococcal group B vaccine (4CMenB) in adults in special situations |
| topic | Medicina 4CMenB Vaccines Meningitis Meningococcus Adverse effects |
| url | https://www.redalyc.org/articulo.oa?id=365962347003 https://www.redalyc.org/journal/3659/365962347003/ https://www.redalyc.org/journal/3659/365962347003/html/ https://www.redalyc.org/journal/3659/365962347003/365962347003.epub https://www.redalyc.org/journal/3659/365962347003/movil |